drugset / Trial / NCT01982747
A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703
RandomizedCrossoverQuadruple-blindTreatment
Summary
MGN1703 is being developed for use in treating cancerous tumors effecting the colon, skin, kidneys and lungs. The dosage form of MGN1703 under investigation is an injection. The goal of this study is to evaluate the effects of MGN1703 on the electrical activity of the heart in healthy subjects and to look at general safety.
Timeline
- Start
- 2013-11
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lefitolimod | Oligonucleotide (other) | 60 mg | Subcutaneous |
Indications
No indication recorded.